PMID: 9546819Jan 1, 1997Paper

Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease

International Psychogeriatrics
M J De LeonL A Saint Louis

Abstract

There is compelling evidence for the early involvement of the hippocampal formation in the natural history of Alzheimer's disease (AD). The evidence comes from recent neuropathology, neuropsychology, and neuroimaging studies. AD-type histopathologic changes limited to the hippocampus have been described and may be seen in normal aging subjects. The sites of maximal neuronal loss in the hippocampal formation are in the CA1, subiculum, and entorhinal cortex. Minimally cognitively impaired (MCI) individuals (defined by ratings of functional capacity and psychiatric symptomatology) exhibit a neuropsychological profile that is distinct from that of the unimpaired elderly. Pathologic evidence suggests that most of these cases already have AD brain changes accentuated in the hippocampal region, and our own longitudinal studies reveal that 70% of this group develop dementia within a 4-year period. We have developed a negative-angle axial view designed to cut parallel to the anterior-posterior plane of the hippocampus. Using this modified axial plane of section in conjunction with computed tomography (CT) and magnetic resonance imaging (MRI), we estimated the prevalence of hippocampal atrophy in normal aging and across severity levels o...Continue Reading

Citations

Feb 19, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Eric GuedjMathieu Ceccaldi
Sep 1, 2009·Brain Imaging and Behavior·Michelle T Fodero-TavolettiVictor L Villemagne
Aug 12, 2008·Molecular Neurobiology·Victor L VillemagneChristopher C Rowe
Dec 13, 2000·Brain Research. Brain Research Reviews·J C de la Torre, G B Stefano
May 5, 2004·Neurobiology of Aging·Corina PennanenHilkka Soininen
May 20, 2000·Annals of the New York Academy of Sciences·J C de la Torre
Mar 22, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·F PortetUNKNOWN MCI Working Group of the European Consortium on Alzheimer's Disease (EADC)
Sep 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·A T DuM W Weiner
Apr 8, 1999·Neuropharmacology·G R Seabrook, T W Rosahl
Nov 23, 2006·IEEE Transactions on Medical Imaging·Oscar CamaraNick C Fox
Oct 29, 2014·Neurocase·Felipe Kenji SudoEliasz Engelhardt
Apr 27, 2005·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Victor L VillemagneC L Masters
Nov 13, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Judith Neugroschl, Kenneth L Davis
Sep 10, 2002·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Brian J BacskaiBradley T Hyman
Mar 30, 2000·Journal of Magnetic Resonance Imaging : JMRI·A BrunettiB Alfano
Dec 5, 2017·Alzheimer Disease and Associated Disorders·Sasinthiran ThiagarajanChristopher Chen
Jan 16, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G WaldemarUNKNOWN EFNS
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Zsigmond Tamas KincsesLászló Vécsei
Feb 12, 2013·Journal of Nuclear Medicine Technology·Christopher C Rowe, Victor L Villemagne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.